美国成人自身免疫性肝炎维持治疗实践相关因素的真实世界证据
本研究基于Optum去标识化Clinformatics Data Mart数据库构建回顾性队列,纳入成人自身免疫性肝炎(AIH)患者,随访至少2年,评估第一年暴露因素与第二年治疗模式的关系。结果显示,2203例有至少1次AIH处方配药的患者中,83.1%接受单一方案超过6个月,其中52.2%为硫唑嘌呤单药治疗;西班牙裔、肝硬化、骨质疏松及医生AIH经验最高五分位与皮质类固醇节约型单药治疗使用较低独立相关;糖尿病、骨质疏松及高经验医生与累积泼尼松用量较高相关。
要点
- 83.1%的患者接受单一方案超过6个月,其中52.2%为硫唑嘌呤单药治疗。
- 西班牙裔、肝硬化、骨质疏松及医生经验最高五分位与皮质类固醇节约型单药治疗使用较低独立相关。
- 糖尿病、骨质疏松及高经验医生与累积泼尼松用量较高相关。
核心结论
- 长期泼尼松治疗仍常见,且在可能因皮质类固醇加重的合并症患者中意外更高。
- 高经验医生更多使用皮质类固醇为基础的治疗可能反映更多治疗难治性疾病。
研究设计与样本
- 回顾性队列研究,数据来自Optum去标识化Clinformatics Data Mart数据库,纳入新发和现有成人AIH患者,所有患者随访至少2年,第一年评估暴露,第二年评估治疗模式。
- 队列女性占81.2%,白人占66.3%,黑人占11.3%,西班牙裔占11.2%,中位年龄61岁。
- 2203例患者有至少1次AIH处方配药。
主要发现
- 83.1%的患者在观察年接受单一方案超过6个月,包括52.2%硫唑嘌呤单药治疗、16.9%硫唑嘌呤/泼尼松联合治疗、13.3%泼尼松单药治疗。
- 布地奈德使用不常见(联合治疗2.1%,单药治疗1.9%)。
- 西班牙裔(aOR: 0.56; p = 0.006)、肝硬化(aOR: 0.73; p = 0.019)、骨质疏松(aOR: 0.54; p = 0.001)及医生AIH经验最高五分位(aOR: 0.66; p = 0.005)与皮质类固醇节约型单药治疗使用较低独立相关。
- 累积泼尼松用量在糖尿病(+441 mg/y; p = 0.004)、骨质疏松(+749 mg/y; p < 0.001)及高经验医生(+556 mg/y; p < 0.001)患者中更高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: While avoidance of long-term corticosteroids is a common objective in the management of autoimmune hepatitis (AIH), prolonged immunosuppression is usually required to prevent disease progression. This study investigates the patient and provider factors associated with treatment patterns in US patients with AIH. APPROACH AND RESULTS: A retrospective cohort of adults with the incident and prevalent AIH was identified from Optum's deidentified Clinformatics Data Mart Database. All patients were followed for at least 2 years, with exposures assessed during the first year and treatment patterns during the second. Patient and provider factors associated with corticosteroid-sparing monotherapy and cumulative prednisone use were identified using multivariable logistic and linear regression, respectively.The cohort was 81.2% female, 66.3% White, 11.3% Black, 11.2% Hispanic, and with a median age of 61 years. Among 2203 patients with ≥1 AIH prescription fill, 83.1% received a single regimen for >6 months of the observation year, which included 52.2% azathioprine monotherapy, 16.9% azathioprine/prednisone, and 13.3% prednisone monotherapy. Budesonide use was uncommon (2.1% combination and 1.9% monotherapy). Hispanic ethnicity (aOR: 0.56; p = 0.006), cirrhosis (aOR: 0.73; p = 0.019), osteoporosis (aOR: 0.54; p =0.001), and top quintile of provider AIH experience (aOR: 0.66; p = 0.005) were independently associated with lower use of corticosteroid-sparing monotherapy. Cumulative prednisone use was greater with diabetes (+441 mg/y; p = 0.004), osteoporosis (+749 mg/y; p < 0.001), and highly experienced providers (+556 mg/y; p < 0.001). CONCLUSIONS: Long-term prednisone therapy remains common and unexpectedly higher among patients with comorbidities potentially aggravated by corticosteroids. The greater use of corticosteroid-based therapy with highly experienced providers may reflect more treatment-refractory disease.
引用
- Bittermann T, Yagan L, Kathawate RG, et al. Real-world evidence for factors associated with maintenance treatment practices among US adults with autoimmune hepatitis. Hepatology. 2024. PMID: 38865589. doi:10.1097/HEP.0000000000000961
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。